Stay updated on Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.

Latest updates to the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page
- Check2 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1; the visible content and functionality of the page appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded a glossary toggle and updated metadata to show 'Last Update Submitted that Met QC Criteria' and Revision: v3.4.0; removed the older QC label, 'No FEAR Act data' wording, and Revision: v3.3.4.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4. No study details or page content were changed.SummaryDifference0.1%

- Check45 days agoChange DetectedNew state-level study locations were added (California, Massachusetts, Texas), and the page revision was updated to v3.3.3.SummaryDifference0.5%

- Check74 days agoChange DetectedPublications section now notes that entries are auto-filled from PubMed and may not pertain to the study, and the page revision is updated to v3.3.2.SummaryDifference0.1%

- Check81 days agoChange DetectedThe funding-lapse disclaimer at the bottom of the page has been removed; this is a non-critical change that does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.